A female patient in her 50s, positive for hepatitis B surface antigen (commonly known as AoA) for more than 20 years, was seen for malaise and found to have a reduced triple system in her peripheral blood. After examination, she was found to have elevated transaminases, a major triplet of hepatitis B (this is the common name for a positive hepatitis B surface antigen, E antigen, and core antibody), and hepatitis B viral DNA of 10^7 copies/mL. She was diagnosed with hepatitis B cirrhosis and hypersplenism. The indication for antiviral therapy was met and the oral nucleoside (acid) analogue, entecavir, was selected. Three months after treatment, the transaminases returned to normal and the virus was undetectable in the blood (commonly referred to as a negative transition). About six months after the sustained negative regression, she discontinued entecavir on her own because she felt much better. About five months after stopping the drug, she developed malaise again and came to the hospital for examination and found that the transaminases were high again and the virus had reappeared. After taking entecavir in time, her condition was stabilized again. This patient had an important problem during her antiviral treatment – unauthorized discontinuation, because oral nucleoside (acid) analogs are not effective against cccDNA, the root cause of hepatitis B virus replication, and relapse after discontinuation may cause great harm to the patient’s body In particular, patients with cirrhosis should not stop taking the medication under the present circumstances. It is important to adhere to the medication and review it regularly.